-- 米国の持株会社オッターテイル(OTTR)は月曜日、第1四半期の小売電力販売量の増加により、電力事業部門の収益が増加したと発表した。 3月31日締めの四半期において、小売電力販売量は前年同期の1.673テラワット時(TWh)から1.716TWhに増加し、事業部門の収益は1億4970万ドルから1億6590万ドルに増加した。 同社によると、料金値上げも収益増加に貢献した。ミネソタ州とサウスダコタ州では、暫定料金がそれぞれ2026年1月と2025年12月に発効した。ノースダコタ州では、改定された基本料金が2025年3月に発効した。 オッターテイルによると、天然ガス火力発電所と石炭火力発電所の発電量増加による燃料回収収入の増加、および投資回収の改善も追い風となった。 同社の製造部門も第1四半期に販売量が4%増加し、売上高は前年同期の8,170万ドルから8,960万ドルに増加しました。 「建設機械市場やレクリエーション車両市場など、当社が事業を展開する一部の市場では需要が改善しました。これは、前年同期の需要低迷と在庫管理の強化とは対照的です」と同社は述べています。 オッターテイル社のプラスチック事業も販売量が7%増加しましたが、平均販売価格が19%下落したため、売上高は前年同期の1億590万ドルから9,160万ドルに減少しました。
Related Articles
Shopify Q1 Net Loss Narrows as Revenue Advances
Shopify's (SHOP.TO), down 5.5% in U.S. pre-market trade, Tuesday reported a narrower first quarter net loss as revenue increased.Net loss narrowed to US$581 million, or US$0.45 per share, from US$682 million, or US$0.53 per share, in the prior year period.Adjusted net income, which excludes the impact of equity investments, rose to US$360 million, from US$226 million.Revenue jumped 34% to US$3.17 billion, from US$2.36 billion, narrowly beating the US$3.1 billion forecast by analysts polled by FactSet.Gross merchandise volume (GMV) which represents the total dollar value of orders facilitated through the Shopify platform including certain apps and channels, reached slightly above US$1 billion, a statement added.For the June quarter, Shopify is guiding for revenue to grow at a high-twenties percentage rate and for gross profit dollars to grow at a mid-twenties percentage rate."Q1 delivered broad-based growth across geographies, merchant sizes, and channels, with over $100 billion of GMV in the first quarter alone," said chief financial officer Jeff Hoffmeister,. "That is the platform compounding. The durability of this model allows us to invest strategically in growth, both in the merchant-facing tools that drive commerce innovation and in the internal capabilities that let us build and ship faster. "Shopify shares were last seen down US$6.45, to US$121.10, in New York trade.
Research Alert: Transdigm Posts Q2 Fy 26 Beat, Strong Sales Growth Masks Margin Contraction
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TransDigm posted Q2 FY 26 (Sep.) results with net sales of $2,544M (+18% Y/Y, 3% above consensus) on 11% organic growth, while adjusted EBITDA rose 15% to $1,337M, with margins compressing 140 bps to 52.6%. Adjusted EPS of $9.85 (+8% Y/Y) beat consensus by $0.38, though the divergence between 18% revenue growth and 12% earnings growth reflects elevated interest costs from debt-funded acquisitions and a negative mix shift. The $2.2B JPE/VSA acquisition represents a strategic shift toward PMA businesses that management acknowledges will not achieve typical TransDigm margins. Management raised FY 26 guidance with sales of $10,300M-$10,420M (+17% Y/Y at midpoint) and adjusted EPS of $38.83-$40.21 (+6% Y/Y). We remain concerned about the aggressive $3.2B acquisition pipeline pressuring leverage and financial flexibility. The strategic pivot toward lower-margin PMA businesses, combined with acquisition dilution, represents a departure from TransDigm's historical margin expansion that warrants scrutiny.
Research Alert: Pfe Q1 Tops Expectations, Fueled By Diversification And Solid Pipeline Progress
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PFE delivered solid Q1 results with adj. EPS of $0.75, down 18% Y/Y but beating the consensus view of $0.72, while revenues grew 5% Y/Y to $14.5B, a solid $700M above the consensus estimate. Excluding Covid products, the underlying business showed robust 7% operational growth, with launched and acquired products delivering 22% Y/Y growth to $3.1B. We view the diversification strategy as positive, with strong oncology momentum including Padcev (+39% Y/Y to $591M) and Lorbrena (+32% Y/Y to $305M) highlighting Pfizer's evolving portfolio strength. Management reaffirmed the 2026 guidance of $59.5B-$62.5B in revenues and $2.80-$3.00 adjusted EPS. We believe the accelerating pipeline momentum is encouraging, with multiple positive Phase 3 readouts including Elrexfio and Padcev studies, plus plans to initiate approximately 20 pivotal studies in 2026. In our view, the company's focus on business development over share repurchases reflects appropriate capital allocation as Pfizer continues its post-Covid transition.